

Toripalimab

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

ATC codes

[L01FF13](#)

Medicine type

Biological agent

EML status history

Application rejected in 2023 ([TRS 1049](#)) for [Malignant neoplasms of nasopharynx](#)

Application rejected in 2023 ([TRS 1049](#)) for [Squamous cell carcinoma of oesophagus](#)

Wikipedia

[Toripalimab](#)

DrugBank

[Toripalimab](#)

Recommendations

Section

Immunomodulators

- Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

[Malignant neoplasms of nasopharynx](#) [Squamous cell carcinoma of oesophagus](#)